Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial-Reference-Cited by-同舟云学术

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial

Published:2020-02-22 Issue:5 Volume:104 Page:443-458
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Schjesvold Fredrik¹²^ORCID,Goldschmidt Hartmut³,Maisnar Vladimir⁴,Spicka Ivan⁵,Abildgaard Neils⁶,Rowlings Philip⁷,Cain Lauren⁸,Romanus Dorothy⁹,Suryanarayan Kaveri¹⁰,Rajkumar Vincent¹¹,Odom Dawn¹²,Gnanasakthy Ari¹³,Dimopoulos Meletios¹⁴^ORCID

Affiliation:

1. Oslo Myeloma Center Oslo University Hospital Oslo Norway

2. KG Jebsen Center for B cell malignancies University of Oslo Oslo Norway

3. Department of Internal Medicine V University Medical Hospital and National Center of Tumor Diseases University of Heidelberg Heidelberg Germany

4. Department of Medicine—Hematology Charles University Hospital Hradec Králové Czech Republic

5. Department of Hematology Charles University Prague Czech Republic

6. Department of Hematology Odense University Hospital University of Southern Denmark Odense Denmark

7. Department of Hematology School of Medicine & Public Health University of Newcastle Waratah New South Wales Australia

8. Statistical and Quantitative Sciences Takeda Pharmaceuticals Cambridge MA USA

9. Global Outcomes Research Takeda Pharmaceuticals Cambridge MA USA

10. Oncology Clinical Research Takeda Pharmaceuticals Cambridge MA USA

11. Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA

12. Biostatistics RTI Health Solutions Research Triangle Park NC USA

13. Patient‐Centered Outcomes Assessment RTI Health Solutions Research Triangle Park NC USA

14. Department of Clinical Therapeutics Hematology & Medical Oncology School of Medicine National and Kapodistrian University of Athens Athens Greece

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13379

Reference37 articles.

1. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools

2. Clinically relevant end points and new drug approvals for myeloma

3. The role of maintenance therapy in multiple myeloma

4. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

5. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

2. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study;Clinical Lymphoma Myeloma and Leukemia;2023-07

3. Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial;eJHaem;2022-08-31

4. Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021;Clinical Lymphoma Myeloma and Leukemia;2022-07

5. Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study;Age and Ageing;2021-10-18